In summary, we report that Myc can activate EZH2 expression in prostate cancer by 2 distinct mechanisms-via direct transcriptional activation of the EZH2 promoter, as well as via repression of miR-26a and miR-26b, which themselves can repress EZH2. The gene discussed is EZH2; the disease is prostate cancer.